Reference : Growth hormone response to apomorphine in obsessive-compulsive disorder.
Scientific journals : Article
Human health sciences : Psychiatry
http://hdl.handle.net/2268/28134
Growth hormone response to apomorphine in obsessive-compulsive disorder.
English
Pitchot, William mailto [Centre Hospitalier Universitaire de Liège - CHU > > Psychiatrie et psychologie médicale >]
Hansenne, Michel mailto [Université de Liège - ULiège > Département des sciences cognitives > Psycho. de la personnalité et des différences individuelles >]
Moreno, A. G. [> > > >]
Ansseau, Marc mailto [Centre Hospitalier Universitaire de Liège - CHU > > Psychiatrie et psychologie médicale >]
1996
Journal of Psychiatry and Neuroscience
Canadian Medical Association
21
5
343-5
Yes (verified by ORBi)
1180-4882
1488-2434
Ottawa
Canada
[en] Adult ; Apomorphine/pharmacology ; Dopamine Agonists/pharmacology ; Female ; Growth Hormone/blood ; Humans ; Male ; Middle Aged ; Obsessive-Compulsive Disorder/blood/complications
[en] Several lines of evidence suggest that dopamine plays a role in the pathophysiology of obsessive-compulsive disorder (OCD). Indeed, some trials have shown the efficacy of neuroleptic addition in the treatment of OCD patients. In this study, we assessed the growth hormone (GH) response to 0.5 mg apomorphine(sc) in 8 drug-free inpatients (6 male, 2 female; mean age +/- SD = 34.7 +/- 12.6) meeting DSM-III-R criteria for OCD without major depression and compared their responses with those of 8 healthy male volunteers (mean age = 27.1 +/- 8.5). The groups did not differ in their mean GH peak response: 12.4 +/- 9.7 ng/mL in OCD patients versus 21.1 +/- 14.2 ng/mL in normal controls (F = 0.9, df1, 14, P = 0.37). These results do not support the hypothesis of dopaminergic overactivity in OCD. In fact, the completely blunted GH response to apomorphine in 2 OCD patients suggests the biological heterogeneity of OCD. Some dopaminergic disturbances could be observed in patients with comorbid diagnoses or patients unresponsive to serotonin reuptake inhibitors, but the results of this study require confirmation from a larger sample with a precise assessment of comorbidity.
http://hdl.handle.net/2268/28134

There is no file associated with this reference.

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.